Active Pharmaceutical Ingredients are chemically and biologically active components of drugs with direct effect in cure, mitigation, treatment and prevention of diseases. The global API market has witnessed tremendous growth over the last few decades owing to the increased use of drugs and biologics in the treatment of diseases. The increasing adoption of quality standards in API manufacturing such as Good Manufacturing Practices (GMP), current GMP (cGMP), and the global adoption of International Conference on Harmonisation (ICH) guidelines, have helped improve the safety standards. On the other hand, the API industry is facing the challenges such as, shortening the development time, reducing the cost of development, improving the process design and meeting the quality standard without compromising on the profitability. The global API market is likely to be impacted by a large number of innovative drugs going off patent in the recent years. There is an impending need for technological innovations to maintain the profitability in high volume and a low value environment. The major factors driving the market growth are, rising incidences of oncology, cardiovascular, diabetes and lifestyle diseases, rising number of hospitals and diagnostic centers, rising geriatric population in developing countries, increasing healthcare expenditure, increasing disease awareness and education. However, a lack of skilled workforce and limited accessibility of drugs in the developing countries are likely to restrict the market growth.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
- Novartis AG,
- Sun Pharmaceutical Industries Ltd.,
- Pfizer, Inc.,
- Teva Pharmaceutical Industries Ltd.,
- Mylan N.V.
- Dr. Reddy’s Laboratories
- Actavis plc
- Lonza Group AG
- Hospira Inc
- . BASF SE
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/1439
๐๐๐ ๐
๐๐๐๐๐๐๐ ๐๐
๐๐๐ ๐๐๐๐๐
- Comprehensive analysis of factors that drive and restrict the growth of the Active Pharmaceutical Ingredients (API) Market is provided
- The report provides a comprehensive analysis of the current market and estimations through 20142020, which would enable the stakeholders to capitalize on prevailing market opportunities
- The projections in the report are made considering the current market trends and market potential for the period of 2014-2020, in terms of value
- An in-depth analysis of key segments of the market demonstrate the types of API along with drugs, manufacturers and therapy areas in the global API market
- SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
- Region-wise Active Pharmaceutical Ingredients (API) market scenario is comprehensively analyzed in the report
๐
๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/1439
The Active Pharmaceutical Ingredients (API) Market is segmented on the basis of API type, drug type, manufacturers, therapy area and geography. On the basis of type of API, the market is segmented into, Chemical API and Biological API. The market is further segmented on the basis of type of drugs into; innovative, generic and Over-the-counter (OTC) drugs. According to market players, the market is segmented into Captive (In-house) manufacturer and Merchant (contract) manufacturer. The market is also segmented on the basis of therapy area into; Oncology Drugs, Non-steroidal Anti-inflammatory Drugs, Cardiovascular Drugs, Anti-diabetic Drugs, Neurology Drugs, Musculoskeletal drugs and others. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA. Inorganic growth through merger and acquisition are the key strategies adopted by top industry players. For instance, Ranbaxy recently acquired Sun Pharmaceutical, a move that helped the company emerge as Indias topmost drug manufacturer. Similarly, in July 2014, Hospira completed the acquisition of the API manufacturing facility and associated R&D facility of Orchid Chemicals & Pharmaceuticals Ltd. The companies profiled in this report include, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories, Actavis plc, Lonza Group AG, Hospira Inc. and BASF SE.
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com